Product Images Metformin Hydrochloride

The text presents a table summarizing changes in major lipid variables after 24 weeks of treatment with Metformin Hydrochloride Tablets. The variables analyzed were: total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The changes in percentage from baseline of each variable were measured at the final visit. However, there is not enough information to make an assessment of the efficacy of the treatment or the clinical relevance of the results.*

The text describes a study with Metformin Hydrochloride Extended Release Tablets in three doses for 24 weeks. The study evaluated the changes in Hemoglobin Ay, Fasting Plasma Glucose, and Body Weight in patients with diabetes. The changes from the baseline were recorded at week 12 and at the final visit. The study included 66 to 72 participants in each group for each measurement, and all patients received 500 mg of Metformin Hydrochloride tablets twice daily at the beginning.*

The text is a table showing the summary of mean percent change from baseline of major serum lipid variables at the final visit, for 29-week studies comparing Metformin Hydrochloride tablets to placebo and combined Metformin Hydrochloride tablets/Glyburide to monotherapy. The variables measured include total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol, and the mean percent change for each variable is reported for each treatment type.*

This appears to be the label of a medication bottle manufactured by NuCare Pharmaceuticals, Inc. The medication is Metformin HCI, a common drug used to treat Type 2 Diabetes. The bottle contains 100 tablets of 1000mg Metformin HCI. The lot number is 000000 and the NDC number is 68071-4525-01. The manufacturer's NDC code is 23155-104-01 and the expiration date is listed as 00-00. The Global Trade Item Number (GTIN) is 0036807452518. The label contains a warning to keep the medication out of the reach of children and to store it at a controlled temperature between 59-86°F.*

This text provides information about a specific group of patients. The patients in question are pediatric and have a mean age of 13.8 years, with a range from 10 to 16 years old. All of the patients are on diet therapy at the beginning of the study. However, the text also notes that there is no statistically significant difference between the patients at the start of the study.*

This is a summary of changes in fasting plasma glucose, HbA, and Body Weight from baseline in a 29-week study comparing Metformin Hydrochloride Tablets to a placebo. The table shows mean changes in FPG, Hemoglobin A, and Body Weight at the final visit. The data shows that Metformin Hydrochloride Tablets produced a significant decrease in FPG and Hemoglobin A compared to the placebo. However, there was no significant difference in Body Weight between the two groups.*

This is a summary of mean changes observed in a study comparing Metformin Hydrochloride Tablets to a placebo in pediatrics patients. The table shows the changes in Plasma Glucose and Body Weight at the final visit of the individuals. The Metformin Hydrochloride Tablets demonstrated a significant reduction in FPG levels with a p-value of less than 0.001 compared to the placebo. A slight increase in body weight was observed in both groups; however, the difference was not significant.*

This is a table that summarizes the results of a 23-week study comparing the combined treatment of Metformin Hydrochloride Tablets and Glyburide to monotherapies of Glyburide or Metformin Hydrochloride Tablets in terms of the mean changes in fasting plasma glucose, HbA1c and body weight from baseline. The results show the p-values for Glyburide vs MET and MET vs Comb. All patients in the study were on Glyburide at baseline, and the changes in most categories were not statistically significant except for body weight reduction in the combined treatment group compared to the monotherapies.*

The table shows a comparison between the mean changes from baseline in HbA and daily insulin dose for a group treated with combined metformin hydrochloride tablets/insulin and another group treated with placebo insulin. The treatment difference is also highlighted. The study shows a statistically significant difference in the final visit for HbA using analysis of covariance with baseline as covariate (p=0.04) but not for insulin.*